Your browser doesn't support javascript.
loading
Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma / 国际肿瘤学杂志
Journal of International Oncology ; (12): 321-326, 2020.
Article in Chinese | WPRIM | ID: wpr-863492
ABSTRACT
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous diseases originating from post-thymic T-cells, with poor prognosis using traditional therapy, especially in patients with relapsed/refractory PTCLs (r/rPTCLs). In recent years, a variety of new anti-tumor drugs have emerged in the treatment of r/rPTCLs, including different types of enzyme inhibitors, monoclonal antibodies, immunomodulators and immune checkpoint inhibitors, which have been proved to be effective. The discovery and clinical application of new drugs are expected to improve the outcomes of the diseases.
Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of International Oncology Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of International Oncology Year: 2020 Type: Article